biostudies-literatureUnknown4(11)Hayashi H<h4>Purpose</h4>Real-world, large-scale studies on the association between immune-related adverse events (irAE) and immune checkpoint inhibitor therapy effectiveness are limited. We evaluated overall survival (OS) and progression-free survival based on the occurrence and grade of irAEs.<h4>Patients and methods</h4>We used data from Japanese patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who received atezolizumab and were enrolled in J-TAIL, a multicenter, prospective, single-arm observational study.<h4>Results</h4>Among the 1,002 patients, 190 (19.0%) developed irAEs. The most common irAEs were skin disorders (3.8%) of any grade and interstitial lung disease (1.5%) of grade ≥3. Patients who developed irAEs within 4 or 6 weeks of treatment initiation hadCancer research communications2858-2867https://www.ebi.ac.uk/biostudies/studies/S-EPMC11528261biostudies-literatureAssociation between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.PMC11528261Takase NTasaka SGemma AFujita MTakamura KYoshino IMouri AGoto YMisumi TKijima TMiura SImaizumi KIwasawa SMitsudomi TAkamatsu HNishio MKondo TKawashima YHayashi HNakagawa SfalseAssociation between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.<h4>Purpose</h4>Real-world, large-scale studies on the association between immune-related adverse events (irAE) and immune checkpoint inhibitor therapy effectiveness are limited. We evaluated overall survival (OS) and progression-free survival based on the occurrence and grade of irAEs.<h4>Patients and methods</h4>We used data from Japanese patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who received atezolizumab and were enrolled in J-TAIL, a multicenter, prospective, single-arm observational study.<h4>Results</h4>Among the 1,002 patients, 190 (19.0%) developed irAEs. The most common irAEs were skin disorders (3.8%) of any grade and interstitial lung disease (1.5%) of grade ≥3. Patients who developed irAEs within 4 or 6 weeks of treatment initiation had2024-01-01T00:00:00Z2024 Nov2026-06-02T23:01:01.856Z2025-04-04T22:47:21.081ZS-EPMC115282613939233910.1158/2767-9764.CRC-24-0212